SPRO
Spero Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SPRO
Spero Therapeutics, Inc.
A multi-asset, clinical-stage biopharmaceutical company focused on novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases
675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139
--
Spero Therapeutics, Inc., formerly known as Spero Therapeutics, LLC, was incorporated in December 2013 under the laws of the State of Delaware. The company is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and marketing new therapies for the treatment of MDR bacterial infections. The company also has a platform technology called "Potential Platform", which the company believes will develop drugs that can expand the scope and potency of existing antibiotics, including previously inactive antibiotics, against Gram-negative bacteria. The company believes that if the new product is successfully developed and approved, it will have meaningful impact and important commercial applications for the treatment of patients with MDR infection in community and hospital settings.
Earnings Call
Q2/2025
Estimate EPS-0.32
Actual EPS-0.03
Estimate Revenue--
Actual Revenue14.19M
Capital Allocation and Trial Timelines: Key Contradictions in Recent Earnings Calls
Aug 12,2025 07:52
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
SPRO has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.25, beating expectations. The chart below visualizes how SPRO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SPRO has released its 2025 Q3 earnings report, with revenue of 5.44M, reflecting a YoY change of -59.60%, and net profit of -7.38M, showing a YoY change of 56.95%. The Sankey diagram below clearly presents SPRO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
